PureTech Health PLC (PRTC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
PureTech Health PLC stock (PRTC) is currently trading at $15.73. PureTech Health PLC PE ratio is 9.33. PureTech Health PLC PS ratio (Price-to-Sales) is 60.01. Analyst consensus price target for PRTC is $46.00. WallStSmart rates PRTC as Underperform.
- PRTC PE ratio analysis and historical PE chart
- PRTC PS ratio (Price-to-Sales) history and trend
- PRTC intrinsic value — DCF, Graham Number, EPV models
- PRTC stock price prediction 2025 2026 2027 2028 2029 2030
- PRTC fair value vs current price
- PRTC insider transactions and insider buying
- Is PRTC undervalued or overvalued?
- PureTech Health PLC financial analysis — revenue, earnings, cash flow
- PRTC Piotroski F-Score and Altman Z-Score
- PRTC analyst price target and Smart Rating
PureTech Health
📊 No data available
Try selecting a different time range
PRTC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · PureTech Health PLC (PRTC)
PRTC trades at a significant discount to its Graham intrinsic value of $79.56, offering a 78% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
PureTech Health PLC (PRTC) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, eps growth. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
PureTech Health PLC (PRTC) Key Strengths (4)
Revenue surging 543.00% year-over-year
Earnings per share surging 61.50% year-over-year
Keeps $793 of every $100 in revenue as net profit
Trading at 1.02x book value, attractively priced
Supporting Valuation Data
PureTech Health PLC (PRTC) Areas to Watch (5)
Losing money on operations
Very expensive at 60.0x annual revenue
Very low institutional interest at 0.39%
Low profitability relative to shareholder equity
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
PureTech Health PLC (PRTC) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.5/10) while 5 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth, Profit Margin. Valuation metrics including Price/Book (1.02) suggest the stock is attractively priced. Profitability is solid with Profit Margin at 793.00%. Growth metrics are encouraging with Revenue Growth at 543.00%, EPS Growth at 61.50%.
The Bear Case
The primary concerns are Operating Margin, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (60.01) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 9.44%, Operating Margin at -2590.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 9.44% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 543.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Revenue Growth, EPS Growth) and negatives (Operating Margin, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRTC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRTC's Price-to-Sales ratio of 60.01x sits near its historical average of 63.03x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 8% below its historical high of 65.15x set in Mar 2026, and 0% above its historical low of 60.01x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for PureTech Health PLC (PRTC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
PureTech Health PLC is a strong growth company balancing expansion with improving profitability. Revenue reached 6M with 543% growth year-over-year. Profit margins are strong at 793.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 543% YoY, reaching 6M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 944.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -46M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can PureTech Health PLC maintain 543%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact PureTech Health PLC.
Bottom Line
PureTech Health PLC offers an attractive blend of growth (543% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About PureTech Health PLC(PRTC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.